Abstract
Two controlled, blinded and randomized multi–site clinical field studies evaluated the efficacy and safety of emodepside/praziquantel spot–on in the treatment of gastrointestinal nematode and cestode infections in cats. In a study conducted in Europe, faecal egg count reductions of >98% for all nematode eggs and eggs of Toxocara cati, respectively, were observed in cats treated with emodepside/praziquantel spot–on (Profender®, Bayer AG, Leverkusen, Germany). For a positivecontrol product containing selamectin (Stronghold) reductions of >95% were observed. A 100% reduction of faecal eggs and proglottids was observed in cats treated with emodepside/praziquantel spot–on that were infected with cestodes. In a study conducted in North America, cats were treated with either emodepside/praziquantel spot–on plus a placebo tablet or a combination of two control products containing, respectively, selamectin (Revolution) and epsiprantel (Cestex). Faecal egg count reduction for eggs of T. cati was >99% for both treatments. For faecal eggs and proglottids of Dipylidium caninum reductions of >99 and >97% were recorded for cats treated with emodepside/praziquantel spot–on and the control group, respectively. No adverse reactions were observed in the European study, and only mild ones of short duration in a few cats from both treatment groups of the North American study. The two studies demonstrated that emodepside/praziquantel spot–on is highly efficacious and safe under field conditions.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Altreuther, G., Buch, J., Charles, S.D. et al. Field evaluation of the efficacy and safety of emodepside/praziquantel spot–on solution against naturally acquired nematode and cestode infections in domestic cats. Parasitol Res 97 (Suppl 1), S58–S64 (2005). https://doi.org/10.1007/s00436-005-1445-0
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00436-005-1445-0